Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Loss per share (basic and diluted)
Basic net loss per share is computed by dividing net loss (the numerator) by the weighted average shares outstanding for the period (the denominator). Diluted net loss per share is computed by dividing net income by the weighted average shares outstanding during the period adjusted for the dilutive effects of the exercise of the stock options. In periods when losses from continuing operations are reported, the weighted-average shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. The computation of net loss per share for the years ended December 31, 2025 and 2024, respectively was as follows:
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| $000s | $000s | |
| Net loss | (88,612) | (45,309) |
| Weighted-average shares outstanding (basic and diluted) | 141,694,702 | 138,752,224 |
| Net loss per share (basic and diluted) | $(0.63) | $(0.33) |
The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact would have been anti-dilutive for the period presented.
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Potentially Dilutive Securities | ||
| Stock options | 20,884,098 | 17,455,390 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.